Alnylam Pharmaceuticals
| Alnylam
|
|
|---|---|
 |
|
| legal form | Incorporated |
| founding | 2002 |
| Seat |
Cambridge , Massachusetts , United States
|
| management | John Maraganore, CEO ; Barry Greene President |
| sales | $ 32.0 million (2016) |
| Branch | pharmacy |
| Website | www.alnylam.com |
Alnylam Pharmaceuticals is an American medical research company that was founded in 2002 and is listed on the American technology exchange NASDAQ under the trademark ALNY. Alnylam is headquartered in Cambridge , MA . The European headquarters are in Maidenhead , UK . The company capitalizes on the discovery of RNA interference by Nobel Prize winners Andrew Z. Fire and Craig C. Mello . The company is co-founded by Nobel Prize winner Phillip Allen Sharp . Alnylam is a spin-off from an institute of the Max Planck Society .
Field of activity
The Alnylam company intends to transfer RNA interference (RNAi or RNA silencing) or gene silencing into a new class of drugs. In the life sciences, RNA interference has established itself as an experimental way to shut down genes (“ gene knockdown ”). For their discovery of the mechanism of RNA interference (in 1998), the two US scientists Andrew Z. Fire and Craig C. Mello received the 2006 Nobel Prize in Physiology or Medicine .
Alnylam is still not making any money, but is writing losses. Alnylam's losses at the end of 2016 were approximately $ 410 million.
Medication / pipeline
Alnylam's research focuses on three strategic therapeutic areas: Hereditary Genetic Diseases , Cardiovascular , Metabolic Diseases and Hepatic Infectious Diseases. Most of the diseases researched by Alnylams are so-called " orphan diseases" ( i.e. rare diseases). So far, the following drugs are still in clinical development :
- Patisiran ( Phase III ): Hereditary ATTR amyloidosis
- Inclisiran / ALN-PCSsc ( phase III ): hypercholesterolemia
- Lumasiran (phase III): primary hyperoxaluria type 1 (PH1)
- Cemdisiran ( phase II ): atypical hemolytic uremic syndrome
- Fitusiran (phase II): hemophilia
- Givosiran / ALN-AS1 (Phase II): Acute Intermittent Porphyria
Cooperations
Alnylam cooperates with Genzyme , a subsidiary of Sanofi , Merck , i.e. Merck Sharp & Dohme (MSD for short), Novartis , The Medicines Company and numerous other companies.
See also
Web links
- Alnylam Pharmaceuticals
- Alnylam Pharmaceuticals share
- Youtube: RNAi, a Promising Potential New Class of Medicines
Individual evidence
- ↑ a b c Our Story , Company WebSite, accessed May 26, 2017
- ↑ a b Contact , Company WebSite, accessed May 26, 2017
- ↑ Our Leadership , Company WebSite, accessed July 26, 2017
- ↑ a b Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Highlights Recent Period Activity ( Memento of the original from June 26, 2017 in the Internet Archive ) Info: The archive link was inserted automatically and has not yet been checked. Please check the original and archive link according to the instructions and then remove this notice. , Company WebSite, accessed May 26, 2017
- ↑ Alnylam Pharmaceuticals, Inc. Real-Time Quotes, NASDAQ WebSite, accessed May 26, 2017
- ↑ Alnylam to Expand Global Footprint with New European Office in Maidenhead, UK , PM of 20 September 2016 businesswire.com, accessed on August 10, 207
- ^ A b The Nobel Prize in Physiology or Medicine 2006 , WebSite Nobelprize.org, accessed May 26, 2017
- ↑ see list of spin-offs at "Max Planck Innovation", visible under "Spin-offs Life Sciences" , accessed May 19, 2020. Max Planck Innovation is a subsidiary of the Max Planck Society.
- ↑ Product Pipeline , Company WebSite, accessed May 26, 2017
- ↑ Alnylam and Sanofi Report Positive Topline Results from APOLLO Phase 3 Study of Patisiran in Hereditary ATTR (hATTR) Amyloidosis Patients with Polyneuropathy ( Memento of September 21, 2017 in the Internet Archive ), PM Alnylam of September 20, 2017, accessed on October 8 2017
- ↑ Onpattro - Opinion , PM EMA, July 26, 2018, accessed July 30, 2018
- ↑ The Medicines Company and Alnylam Pharmaceuticals Announce Agreement with FDA on Phase III Clinical Program for Inclisiran ( Memento of 26 June 2017 Internet Archive ), PM Alnylam of 26 April 2017 called on May 26, 2017
- ↑ The Medicines Company and Alnylam Pharmaceuticals Report Positive Final Results from ORION-1 Phase II Study of Inclisiran ( Memento of the original from June 30, 2017 in the Internet Archive ) Info: The archive link was inserted automatically and has not yet been checked. Please check the original and archive link according to the instructions and then remove this notice. , PM Alnylam, March 17, 2017, accessed July 24, 2017
- ↑ The Medicines Company and Alnylam Pharmaceuticals Announce Initiation of Phase III Clinical Trials of Inclisiran , PM The Medicines Company, November 6, 2017, accessed December 4, 2017
- ↑ The Medicines Company Announces Inclisiran Data Showing Significant Reductions in Potentially Harmful Subtypes of Bad Cholesterol (Atherogenic Lipoproteins) Linked to Heart Attack and Stroke , PM The Medicines Company, May 7, 2018, accessed May 20, 2018
- ↑ Alnylam Achieves Alignment with FDA on Accelerated Development Path for Lumasiran, an Investigational RNAi Therapeutic for the Treatment of Primary Hyperoxaluria Type 1 (PH1) , PM Alnylam, May 3, 2018, accessed May 20, 2018
- ↑ Alnylam Initiates Phase 2 Clinical Study of Cemdisiran (ALN-CC5) in Patients with Atypical Hemolytic-Uremic Syndrome (aHUS) ( Memento of the original from October 9, 2017 in the Internet Archive ) Info: The archive link has been inserted automatically and has not yet been checked. Please check the original and archive link according to the instructions and then remove this notice. , PM Alnylam, September 26, 2017, accessed October 8, 2017
- ^ Initial Evidence of Clinical Activity Shown with Givosiran (ALN-AS1) in Acute Intermittent Porphyria Patients with Recurrent Attacks , PM Alnylam, March 12, 2016, accessed May 27, 2017
